Amylin sued Lilly, alleging Lilly's diabetes venture with Boehringer Ingelheim is anticompetitive and breaches strategic alliance agreements.
WSJ.com: US Business, Wall Street Journal: Business
Mon, 05/16/2011 - 6:01am
Amylin sued Lilly, alleging Lilly's diabetes venture with Boehringer Ingelheim is anticompetitive and breaches strategic alliance agreements.